A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study
A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus- a randomized controlled trial START-J study
复制标题
DOI：
10.1186/1475-2840-13-96
复制
发表时间：
2014-05-24
影响因子：
9.3
通讯作者：
Shimomura, Iichiro
中科院分区：
文献类型：
--
作者：
Hibuse, Toshiyuki;Maeda, Norikazu;Shimomura, Iichiro
背景：二肽基肽酶-IV（DPP-4）抑制剂，包括西格列汀，用于治疗2型糖尿病（T2 DM）。脂联素是一种脂肪细胞来源的循环蛋白，具有抗动脉粥样硬化和抗糖尿病的特性，并能被胰岛素增敏剂噻唑烷二酮类有效地升高。然而，在日本T2 DM患者中，尚未完全阐明西格列汀治疗对T2 DM患者血清脂联素水平的影响。本研究的目的是研究西格列汀治疗对T2 DM受试者血清脂联素水平的影响。方法：2011年4月至2013年3月期间，连续招募了26名日本T2 DM门诊患者，随机分为对照组（常规治疗，n = 10）和西格列汀治疗组（n = 16）。结果：治疗3个月后，对照组和西格列汀组的糖化血红蛋白、糖化白蛋白和1.5-脱水-D-葡萄糖醇等血糖控制指标均明显改善。西格列汀组血清脂联素水平从6.7 +/- 0.8 μ g/mL显著升高至7.4 +/- 1.0 μ g/mL，而体重指数无变化（p = 0.034），而对照组的血清脂联素水平没有改变结论：在日本T2 DM患者中，西格列汀治疗3个月后血清脂联素水平升高，而体重无变化。
Background: The dipeptidyl-peptidase-IV (DPP-4) inhibitors, including sitagliptin, are used for the treatment of type 2 diabetes mellitus (T2DM). Adiponectin, an adipocyte-derived circulating protein, has anti-atherosclerotic and anti-diabetic properties and is effectively elevated in bloodstream by thiazolidinediones, an insulin sensitizer. However, the effect of sitagliptin treatment on serum adiponectin level in T2DM has not fully elucidated in Japanese T2DM patients. The aim of the present study was to examine the effect of sitagliptin treatment on serum adiponectin levels in T2DM subjects.Methods: Twenty-six consecutive Japanese T2DM outpatients were recruited between April 2011 and March 2013, and randomized into the control (conventional treatment, n = 10) group and sitagliptin treatment group (n = 16). Serum adiponectin was measured by enzyme-linked immunosorbent assay.Results: Indices of glycemic control, such as hemoglobin A1c, glycated albumin, and 1.5-anhydro-D-glucitol, were significantly improved after the three-month treatment in both the control and sitagliptin groups. Serum adiponectin level was significantly increased in sitagliptin group from 6.7 +/- 0.8 to 7.4 +/- 1.0 mu g/mL without change of body mass index (p = 0.034), while serum adiponectin level was not altered in the control group (p = 0.601).Conclusion: In Japanese T2DM patients, serum adiponectin level was elevated by three-month treatment with sitagliptin without change of body weight.